SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: In vitro anti-inflammatory actions

Journal of Pharmacology and Experimental Therapeutics

Volumn 284, Issue 1, 1998, Pages 420-426

  Barnette, Mary S ^a   Christensen, Siegfried B ^a   Essayan, David M ^b   Grous, Marilyn ^a   Prabhakar, Uma ^a   Rush, Julia A ^a   Kagey Sobotka, Anne ^b   Torphy, Theodore J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 CYANO 4 [3 CYCLOPENTYLOXY 4 METHOXY PHENYL] 1 CYCLOHEXANECARBOXYLIC ACID; AMINOPHENAZONE; CYCLIC AMP; CYTOKINE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; GAMMA INTERFERON; HISTAMINE; HOUSE DUST ALLERGEN; INTERLEUKIN 5; LIPOPOLYSACCHARIDE; MYELOPEROXIDASE; PHOSPHODIESTERASE IV INHIBITOR; RAGWEED ANTIGEN; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BASOPHIL DEGRANULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; HISTAMINE RELEASE; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; MALE; MONOCYTE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RABBIT; STOMACH ACID SECRETION; STOMACH GLAND;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTRIC ACID; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; PYRROLIDINONES; RABBITS; ROLIPRAM;

EID: 0031911575     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Barnette MS, Christensen SB, Essayan DM, Esser KM, Grous M, Huang S-K, Manning CD, Prabhakar U, Rush J and Torphy TJ (1994) SB 207499, a potent and selective phosphodiesterase (PDE) IV inhibitor suppresses activities of several immune and inflammatory cells (Abstract). Am J Resp Crit Care Med 149:A209.
2. Barnette MS, Christensen SB, Underwood DC and Torphy TJ (1996a) Phosphodies-terase 4: Biological underpinnings for the design of improved inhibitors. Pharmacol Rev Commun 8:65-73.
3. Barnette MS, Grous M, Cieslinski LB, Burman M, Christensen SB and Torphy TJ (1995a) Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in isolated rabbit gastric glands: Correlation between function and interaction with a high affinity rolipram-binding site. J Pharmacol Exp Ther 273:1396-1402.
4. Barnette MS, Manning CD, Cieslinski LB, Burman M, Christensen SB and Torphy TJ (1995b) The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea-pig eosinophils is correlated with inhibition of PDE IV catalytic activity. J Pharmacol Exp Ther 273:674-679.
5. 3H]-rolipram binding. Biochem Pharmacol 51: 949-956.
6. Berglindh T and Obrink KJ (1976) A method for preparing isolated glands from the rabbit gastric mucosa. Acta Physiol Scand 96:150-159.
7. 2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 146:108-113.
8. Christensen SB, Guider AM, Forster CJ, Gleason JG, Bender PE, Karpinski JM, Barnette MS, Cieslinski LB, Burman M, Underwood DC, Manning CD, Grous M, Griswold DE, Ryan DS, Eggleston DS and Torphy, TJ (1997) 1,4-Cylcohexane carboxylates: Potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. J Med Chem (in press).
9. Collata F, Peri G, Villa A and Mantovani A (1984) Rapid killing of actinomycin-D treated tumor cells by human mononuclear cells. J Immunol 132:936-944.
10. Crocker IC, Townley RG and Khan MM (1996) Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells. Immunopharmacology 31:223-235.
11. DiSanto ME and Heaslip RJ (1993) Identification and stabilzation of large molecular weight PDE IVs from U937 cells. Biochem Biophys Res Commun 197:1126-1131.
12. Essayan DM, Huang S-K, Kagey-Sobotka A and Lichenstein LM (1995) Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene expresseion in peripheral blood mononuclear cells. Am J Respir Cell Mol Biol 13:692-702.
13. Essayan DM, Huang S-K, Undem BJ, Kagey-Sobotka A and Lichtenstein LM (1994) Modulation of antigen-and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Immunol 153:3408-3416.
14. Giembycz MA (1992) Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma? Biochem Pharmacol 43:2041-2051.
15. Heaslip RJ and Evans DY (1995) Emetic, central nervous system and pulmonary activities of rolipram in the dog. Eur J Pharmacol 286:281-290.
16. Horowski R and Sastre-Y-Hernandez M (1985) Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: Global evaluation of the preliminary reports. Curr Ther Res 38:23-29.
17. Huang S-K, Essayan DM, Krishnaswamy G, Yi M, Kumai M, Su S-N, Xiao H-Q, Lichtenstein LM and Liu MC (1994) Detection of allergen-and mitgen-induced human cytokine transcripts using a competitive polymerase chain reaction. J Immunol Methods 168:167-181.
18. Jacobitz S, McLaughlin MM, Livi GP, Burman M and Torphy TJ (1996) Mapping the functional domains of human recombinant phosphodiesterase 4A: Structural requirements for catalytic activity and rolipram binding. Mol Pharmacol 50:891-899.
19. Kohler G and Milstein C (1975) Continuous culture of fused cells secreting antibody of predefined specificty. Nature 256:495-497.
20. Nielson CP, Vestal RE, Sturm RJ and Heaslip R (1990) Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol 86:801-808.
21. Peachell PT, Undem BJ, Schleimer RP, MacGlashan DW, Lichtenstein LM, Cieslinski LB and Torphy TJ (1992) Preliminary identification and role of phosphodiesterase isozymes in human basophils. J Immunol 148:2503-2510.
22. Puuruhen J, Lucke C and Schwabe U (1978) Effect of the phosphodiesterase inhibitor 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711) on gastric secretion and gastric mucosal cyclic AMP. Naunyn-Schmiedeberg's Arch Pharmacol 304:69-75.
23. Sack J and Spenney JG (1982) Aminopyrine accumulation by mammalian gastric glands: An analysis of the technique. Am J Physiol 243:G313-G319.
24. Schmiechen R, Schneider HH and Watchel H (1990) Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase. Psychopharmacology 102:17-20.
25. Schneider HH, Schmiechen R, Brezinski M and Seidler J (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 127:105-115.
26. Semmler J, Wachtel H and Endres S (1993) The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-a production by human mono-nuclear cells. Int J Immunopharmacol 15:409-413.
27. Siraganian RP (1974) An automated continuous-flow system for the extraction and fluorometric analysis of histamine. Anal Biochem 57:383-395.
28. Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, Pollock K, Palfreyman MN and Karlsson, J-A (1996) Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br J Pharmacol 118:649-658.
29. Torphy TJ, Christensen SB, Barnette MS, Burman M, Cieslinski LB and DeWolf WE Jr (1997) Molecular basis for an improved therapeutic index of SB 207499, a second-generation phosphodiesterase 4 inhibitor (Abstract). Eur Respir J 10:313s.
30. Torphy TJ, DeWolf WE, Green DW and Livi GP (1993) Biochemical characteristics and cellular regulation of phosphodiesterase IV. Agents Actions 43S:51-71.
31. Torphy TJ, Murray KJ and Arch JRS (1994) Selective phosphodiesterase isozyme inhibitors, in Drugs and the Lung (Page CP and Metzger WJ, eds) pp 397-447, Raven Press, New York.
32. Torphy TJ, Stadel JM, Burman M, Cieslinski LB, McLaughlin MM, White JR and Livi GP (1992a) Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J Biol Chem. 267:1798-1804.
33. Torphy TJ and Undem BJ (1991) Phosphodiesterase inhibitors: New apportunities for the treatment of asthma. Thorax 46:512-523.
34. Torphy TJ, Zhou H-L and Cieslinski LB (1992b) Elevation of cyclic AMP content in U937 cells increases the activity of the cyclic AMP-specific phosphodiesterase. J Pharmacol Exp Ther 263:1195-1204.
35. Underwood DC, Osborn RR, Novak LB, Matthews JK, Newsholme SJ, Undem BJ, Hand JM and Torphy TJ (1993) Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the phosphodiesterase IV inhibitor, rolipram. J Pharmacol Exp Ther 266:306-313.
36. Verghese MW, McConnell RT, Strickland AB, Gooding RC, Stimpson SA, Yarnall DP, Taylor JD and Furdon PJ (1995) Differential regulation of human monocyte-derived TNFα and IL-1β by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J Pharmacol Exp Ther 272:1313-1320.
37. Winston SE, Fuller SA and Hurrel JGR (1987) Enzyme-linked immunosorbant assay (ELISA) for detection of antigens, in Current Protocols in Molecular Biology (Ausubel FM, Brente R, Kingston EE, Moore DD, Seidman JG, Smith JA and Strubel K, eds) pp 11.2.1-11.2.0, John Wiley and Sons, New York.